Medical history of chemotherapy or immunosuppressive drug treatment and risk of amyotrophic lateral sclerosis (ALS).

Autor: Kuczmarski T; Department of Neurology, Dartmouth-Hitchcock Medical Center, 7936 Rubin Building, One Medical Center Drive, Lebanon, NH, 03756, USA., Stommel EW; Department of Neurology, Dartmouth-Hitchcock Medical Center, 7936 Rubin Building, One Medical Center Drive, Lebanon, NH, 03756, USA., Riley K; Department of Neurology, School of Medicine, Johns Hopkins University, Baltimore, MD, USA., Tandan R; Department of Neurological Sciences, University of Vermont Medical Center, Burlington, VT, USA., Chaudhry V; Department of Neurology, School of Medicine, Johns Hopkins University, Baltimore, MD, USA., Clawson L; Department of Neurology, School of Medicine, Johns Hopkins University, Baltimore, MD, USA., Caller TA; Cheyenne Regional Medical Center, Medical Specialty Clinic, Cheyenne, WY, USA., Henegan PL; Department of Neurology, Dartmouth-Hitchcock Medical Center, 7936 Rubin Building, One Medical Center Drive, Lebanon, NH, 03756, USA., Facciponte DN; Department of Neurology, Dartmouth-Hitchcock Medical Center, 7936 Rubin Building, One Medical Center Drive, Lebanon, NH, 03756, USA., Bradley WG; Department of Neurology, Miller School of Medicine, University of Miami, Miami, FL, USA., Andrew AS; Department of Neurology, Dartmouth-Hitchcock Medical Center, 7936 Rubin Building, One Medical Center Drive, Lebanon, NH, 03756, USA. Angeline.Andrew@dartmouth.edu.
Jazyk: angličtina
Zdroj: Journal of neurology [J Neurol] 2017 Aug; Vol. 264 (8), pp. 1763-1767. Date of Electronic Publication: 2017 Jul 15.
DOI: 10.1007/s00415-017-8564-2
Abstrakt: A recent population-based analysis demonstrated lower risk of the lethal degenerative neuromuscular disease, amyotrophic lateral sclerosis (ALS) associated with history of the use of 'antineoplastic agents' and 'immunosuppressants'. To see if this finding was generalizable to other ALS cohorts, we examined associations between use of these agents and ALS risk in an independent case-control study of n = 414 ALS patients and n = 361 controls in an Eastern US population. Controls were sampled from the general population and among non-neurodegenerative disease patients. A history of chemotherapy treatment was significantly associated with a decreased ALS risk (OR 0.46, 95% CI 0.22-0.89, P = 0.026). We did not observe an association between risk of ALS and immunosuppressant therapy use (OR 0.78, 95% CI 0.50-1.02, P = 0.23). Analyses were adjusted for age, gender, and smoking. Our results support the prior report for chemotherapy treatment and lead to further discussion of the underlying mechanism.
Databáze: MEDLINE
Externí odkaz: